ACE1831 is a special kind of medicine made from healthy donor cells to treat certain blood cancers called CD20-expressing B-cell malignancies. These are cancers that have a specific protein called CD20 on their surface. The study is a Phase I trial, which means it is the first time this medicine is being tested in humans. The main goal is to see if ACE1831 is safe and how well it works for people with Non-Hodgkin lymphoma after other treatments have failed. Participants need to have received at least two other treatments before joining this study.

• The study involves checking safety and how the body handles the drug.
• Participants must meet specific health criteria and cannot have certain conditions.
• No compensation is mentioned, and participants must agree to follow study rules.